Tumour microenvironment factors shaping the cancer metabolism landscape

Dimitrios Anastasiou*,1

1Cancer Metabolism Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK

Cancer cells exhibit metabolic alterations that distinguish them from healthy tissues and make their metabolic processes susceptible to pharmacological targeting. Although typical cell-autonomous features of cancer metabolism have been emerging, it is increasingly appreciated that extrinsic factors also influence the metabolic properties of tumours. This review highlights evidence from the recent literature to discuss how conditions within the tumour microenvironment shape the metabolic character of tumours.

A primary goal in designing new cancer therapies is to target cancer cells specifically and, at the same time, spare healthy tissues. Cancer cells exhibit, among others, characteristic features in the way they utilise nutrients to survive and proliferate. Although in many cases the ensemble of small molecules and enzymatic activities underlying metabolic processes in cancer are, by and large, similar to the ones in healthy tissues, changes in the expression levels of metabolic enzymes, expression of alternative enzyme isoforms or mutations in genes encoding metabolic enzymes have all been implicated in altering the metabolism of tumours (Pavlova and Thompson, 2016). Oncogenic and tumour suppressor pathways that drive cancer development have been shown to promote these metabolic features, which are therefore stably propagated throughout tumour development. This has raised hopes that metabolic enzymes comprise good targets for cancer therapy (Galluzzi et al, 2013; Elia et al, 2016).

Metabolism encompasses the chemical processes that allow cells to use available nutrient resources and sustain their survival and propagation. As such, the environment in which tumours emerge is bound to have an influence in their metabolism: what nutrients and other factors that enable metabolism, such as oxygen, are available, at what quantities, whether other cells are present that compete for or provide such nutrients are all factors that can influence the metabolic behaviour of tumours.

This review focuses on recent advances in our understanding of cancer metabolism with emphasis on the influence of the tumour microenvironment. In particular, I will discuss work in mice and humans that points to a synergism between the tumour environment and genetics in determining the metabolic profiles of cancers, and will put this evidence in context of the prevailing views on how glucose and glutamine support cancer metabolism. I will then explore factors that are thought to operate within the tumour environment, in particular fluctuations in oxygen and nutrient availability, and will describe newly discovered mechanisms by which these factors impact metabolism. Finally, I will use select examples to outline how various tumour stromal cells, which are also subject to similar metabolic requirements as cancer cells, contribute to the metabolic conditions found within the tumour microenvironment.

OVERVIEW OF CENTRAL METABOLISM—GLUCOSE AND GLUTAMINE

Glucose is an abundant source of carbon in mammals, and organs such as the brain and the heart exhibit high levels of glucose uptake. Some tumours show increased glucose uptake relative to the surrounding normal tissues and this feature has been exploited for diagnostic imaging using 18F-deoxyglucose (FDG), a radioactive glucose analogue that cannot be fully metabolised, for positron emission tomography (PET).

Glucose uptake can be promoted by gene expression or signalling changes that lead to increased glucose transporter expression, particularly GLUT1, at the plasma membrane. Once into cells, a major route for glucose catabolism is glycolysis (Figure 1). Pathways that branch out of glycolysis can utilise products of glucose catabolism for the synthesis of nucleotides, lipids or amino acids. Depending on cell type and environmental conditions, glucose-derived pyruvate enters into the mitochondrial TCA cycle as an intact 3-carbon unit via pyruvate carboxylase, or...
loses one carbon as CO$_2$ and is converted to acetyl-coA by pyruvate dehydrogenase (PDH). Carbon metabolism in the TCA cycle can further provide metabolic intermediates for biosynthesis of lipids and amino acids, which, in addition to protein, are also precursors for nucleotides and glutathione. Furthermore, the TCA cycle concomitantly produces reducing power in the form of NADH and FADH$_2$ to generate the proton motive force across the inner mitochondrial membrane required for ATP synthesis (DeBerardinis and Chandel, 2016).

A prevailing picture is that, in tumours, a higher fraction of glucose carbons is diverted away from mitochondria and converted to lactate by lactate dehydrogenase (LDH), a phenomenon referred to as the Warburg effect. Decreased catabolism of glucose in mitochondria had initially been attributed to mitochondrial dysfunction, raising the apparent paradox of how cancer cells can cope with a metabolic state that yields less energy per glucose molecule. However, there is little evidence that ATP is limiting for the growth of cancer cells (Israelsen and Vander...
Cellular metabolites have vastly diverse physicochemical properties, thereby necessitating the combination of various analytical methods for their detection and quantification. In some cases, the presence of a specific metabolite may inform of the metabolic state of a tumour; however, it is not always straightforward to infer the activity of specific metabolic pathways from the measurement of metabolite abundances alone (Buescher et al., 2015). The use of stable isotope tracers has been pivotal in analysing how specific metabolites are catabolised through various pathways by following the distribution of the labelled element in other molecules.

Administration of $^{13}$C-labelled glucose in human lung cancer patients identified increased contribution of glucose carbons to the TCA cycle, as well as lactate compared with non-cancerous extra-tumoral tissue (Sellers et al., 2015; Hensley et al., 2016). Interestingly, both pyruvate carboxylase (PC) and PDH can catalyse the entry of pyruvate into the TCA cycle, but the relative contribution of PDH exceeds that of PC (Hensley et al., 2016). Similarly, PDH was found to be essential for the growth of autochthonous lung tumours driven by oncogenic Ras in mice (Davidson et al., 2016). High-glucose catabolism in mitochondria through PC has also been observed in human glioblastoma tumours of diverse genetic backgrounds (Marin-Valencia et al., 2012). In all these cases, glucose catabolism contributed little to the TCA cycle and cells from the respective tumours were resilient to glutamine withdrawal or inhibition of glutaminolysis. These data also resonate with observations of increased flux through PC in tumours that harbour TCA cycle enzyme mutations (Cardaci et al., 2015), or following genetic ablation of glutamine-dependent anaplerosis (Cheng et al., 2011). The reciprocal relationship between PC and glutamine catabolism through the TCA cycle reflects the importance of anaplerosis for sustaining TCA cycle functions.

In some tumour settings, decreased reliance on anaplerosis from exogenous glutamine is associated with the ability of these tumours to synthesise glutamine from glucose. Efflux of glucose carbons towards glutamine synthesis would also explain the co-existence of PD and PDH to provide both substrates required for citrate synthase (OAA and acetyl-coA) and maintain TCA cycle activity. Curiously, glutamine synthesis seems to operate in parallel to increased uptake of glutamine from the surrounding milieu, although the contribution of circulating glutamine to the latter may differ depending on the experimental model (Marin-Valencia et al., 2012; Tardito et al., 2015). Regardless, this evidence suggests that glutamine catabolism in pathways other than the TCA cycle remains important for the growth of tumours that oxidise glucose to $\text{CO}_2$, in particular for providing nutrients for de novo purine biosynthesis (Tardito et al., 2015).

The balance between glutamine synthesis and production is determined, to a certain degree, by the genetic background of the tumour. Mouse liver tumours induced by the Met oncogene synthesise glutamine, whereas Myc-induced liver tumours consume glutamine (Yuneva et al., 2012). In contrast, Myc-induced tumours in the mouse lung exhibit net glutamine synthesis. These differences may reflect an influence of the tissue and cell type from which tumours originate on whether specific metabolic gene loci can be expressed (Hoadley et al., 2014). However, in human lung tumours from the same patient, heterogeneity in their ability to oxidise glucose correlates better with the perfusion status of each tumour than its genetic background (Hensley et al., 2016). Notably, in an orthotopic mouse mammary gland tumour model, metastases in the lung exhibited increased reliance on PC-dependent anaplerosis compared with the primary tumour in vivo. Estimates of mitochondrial pyruvate concentrations based on the distribution
of isotopic labelling patterns and metabolic modelling, hinted that this behaviour could arise from increased intracellular pyruvate concentrations that fall within the optimal range for PC activity (Christen et al, 2016). In cultured cells, increased extracellular pyruvate concentrations led to proportional increases in intracellular pyruvate, supporting the notion that substrate availability at the metastatic site is one factor through which the niche influences the metabolic signature of a tumour. Direct evidence that the microenvironment modulates tumour metabolism in a manner that is epistatic over its genetic background was provided in experiments where mouse lung cancer cells were isolated, cultured under standard conditions and re-introduced back into animals. These cells showed a propensity to excrete glucose-derived lactate and relied more on glutamine anaplerosis in contrast to the tumours they were derived from, which showed high-glucose oxidation and low-glutamine anaplerosis of the TCA cycle in vivo. When these cells were re-implanted into mouse lungs, they recovered the metabolic characteristics of the original tumours (Davidson et al, 2016).

Taken together, these observations shed fresh light into the use of glucose and glutamine in different autochthonous models of cancer and suggest that the metabolism of cancer cells is malleable to factors in their environment.

**METABOLIC ADAPTATION TO LIMITING OXYGEN AND NUTRIENT CONCENTRATIONS**

Remodelling of tissues during tumour development involves the convergence of various cell types, including fibroblasts, immune cells and endothelial cells (Juntila and de Sauvage, 2013) each with varying metabolic requirements (Ghesquiere et al, 2014). This combined with changes in nutrient and oxygen concentrations due to the dynamics of vasculature as tumours increase in mass, shape the tumour metabolic landscape in a complex manner that involves both cell-autonomous and non cell-autonomous mechanisms.

It is not entirely clear how tumours cope with low nutrient and oxygen concentrations between the time such deficits are sensed, suitable cellular responses are elicited and new vasculature is ultimately established. Early responses to acute drops in oxygen tension are mediated by changes in mitochondrial metabolism and, in particular, the generation of ROS (Chandel et al, 1998; Figure 2).

---

Figure 2. Overview of key metabolic pathways implicated in the response of cancer cells to low oxygen conditions. See text for details. ACSS2, Acetyl-CoA synthase isoform 2; HIF, hypoxia-inducible factor; FFAs, free fatty acids; other abbreviations are as in Figure 1.
However, ROS can also react with various biomolecules, so tumour cells employ various mechanisms to maintain ROS homeostasis. NADPH is central to the ability of cells to control ROS through its use for re-generating antioxidants such as glutathione. Deuterium tracing analyses revealed a significant contribution of glucose to NADPH production via the pentose phosphate pathway (PPP) for anti-oxidant functions (Fan et al, 2014). Oncogenes that activate the phosphoinositide-3-kinase pathway lead to increased glucose uptake and utilisation through the PPP to produce NADPH, and support survival following an acute increase in ROS associated with matrix detachment (Schafer et al, 2009), a cardinal feature of transformed cells. In hypoxia, glucose utilisation through the PPP can be promoted by direct modification of metabolic enzymes by ROS (Anastasiou et al, 2011) or glycosylation (Yi et al, 2012). In some settings, the anti-oxidant roles of glucose catabolism in hypoxia involve its turnover through glycogen, a polymer normally used to store glucose in specific healthy tissues, such as the liver and muscle. Glycogen accumulates in various cancer cell lines and hypoxic tumours, and inhibition of glycogen breakdown results in p53-induced senescence due to high levels of ROS (Favaro et al, 2012). What advantages utilisation of glycogen-derived glucose vs exogenous glucose confer is not entirely clear. One possibility is that glycogen may provide a dedicated pool of PPP precursors that can be mobilised, perhaps more readily or at the required intracellular location and after only certain stimuli, while sparing free glucose for other functions.

Concomitantly, ROS, alongside inhibition of prolyl hydroxylases (PHDs), are essential for the long-term survival of hypoxic tumours by stabilising the hypoxia-inducible factor (HIF) family of transcription factors (Majmundar et al, 2010). Genes controlled by HIF1 include PDH kinase (PDK) and LDH. Inhibition of PDH activity through phosphorylation by PDK, and expression of LDH, lead to decreased entry of glucose-derived carbons into the TCA cycle and increased conversion of pyruvate into lactate (Papandreou et al, 2006; Figure 2).

To make glucose available for anti-oxidant functions in hypoxia, glutamine can sustain both ATP production (Fan et al, 2013) and lipid synthesis (Metallo et al, 2012). The latter is dependent on HIF through an incompletely understood mechanism that involves the reductive carboxylation of glutamine. A similar pathway for glutamine utilisation has also been observed during anchorage-independent growth (Jiang et al, 2016), lending further credence to a role for reductive glutamine metabolism under conditions that are relevant within the tumour microenvironment. In this setting, utilisation of glutamine reductively afforded cells an enhanced ability to detoxify mitochondrial ROS through NADPH produced by the mitochondrial IDH2 reaction. It is unclear whether this re-configuration of glutamine metabolism also reflects a actual need for more lipids, as the role of de novo lipogenesis in hypoxic tumour growth and survival is likely context specific (Kamphorst et al, 2013). Furthermore, in various physiological settings when extracellular fatty acids are abundant, de novo lipogenesis is suppressed, suggesting that lipid metabolism may be further influenced by the availability of metabolic precursors also in hypoxia (Duarte et al, 2014; Yao et al, 2016).

Hypoxic cells accumulate lipid droplets that are essential for their survival, especially following re-oxygenation, where they have been proposed to provide an alternative-to-glucose source of antioxidants, as well as help maintain ATP levels through fatty acid oxidation (Bensaad et al, 2014; Figure 2). Although the precise mechanism for the anti-oxidant function of lipid droplets in cancer cells is not clear, a cytoprotective role in hypoxia has been demonstrated in the developing Drosophila brain, where triglycerides in lipid droplets serve as a depot for polyunsaturated fatty acids, which are particularly susceptible to oxidative damage, thereby preventing the accumulation of harmful peroxidised lipids in cellular membranes (Bailey et al, 2015). Interestingly, overall fatty acid synthesis in hypoxia is suppressed (Metallo et al, 2012; Kamphorst et al, 2013; Bensaad et al, 2014); however, glucose contributes a large fraction of the glycerol backbone of polar lipids (Schug et al, 2015). If this were also the case for triglycerides, the main component of the lipid droplet core, it would help explain the increase in lipid droplet content.

On the other hand, increased uptake of exogenous free fatty acids by plasma membrane fatty acid carriers can provide the fatty acid moiety of lipids (Bensaad et al, 2014), and, in some experimental models, hypoxic cells preferentially deplete lysophospholipids from their media (Kamphorst et al, 2013). Furthermore, hypoxic cells can utilise acetate as the main source of acetyl-CoA for lipid synthesis due to the increased expression of acetyl-CoA synthase 2 (Kamphorst et al, 2014; Schug et al, 2015). An increased contribution of acetate to acetyl-CoA and histones has also been observed in mouse liver cancer models (Comerford et al, 2014), orthotopically implanted human GBM tumours in mice, as well as human patients (Mashimo et al, 2014), which could reflect an increased presence of hypoxic regions in these tumours (Schug et al, 2015).

Deprivation of serum nutrients and hypoxia likely coincide in poorly vascularised tumours and can synergise in shaping the metabolic behaviour of hypoxic cells, although the relative sensitivity of cancer cells to these factors may be determined by both cell extrinsic (e.g., the relative diffusion of lipids vs oxygen through tissues) and intrinsic mechanisms (e.g., the underlying oncogenic driver; Kamphorst et al, 2013; Li et al, 2013; Padanad et al, 2016; Peck et al, 2016). Emerging evidence points to an important role of the tumour stroma as a source of nutrients in the poorly irrigated tumour.

Increased autophagy in pancreatic stellate cells provides sufficient alanine to surrounding cancer cells to fuel TCA cycle-dependent biosynthetic processes (Sousa et al, 2016). Similarly, autophagy in primary cancer-associated fibroblasts (CAFs) results in elevated levels of dipeptides (two covalently bound amino acids; Chaudhri et al, 2013). The metabolic fate of dipeptides in vivo remains to be elucidated, however, CAFs derived from lung tumours that showed low glucose uptake had increased levels of dipeptides, suggesting that CAFs may provide an alternative source of carbon for neighbouring cancer cells. Metabolic synergism between cells in the tumour microenvironment where non-cancer cells are spared has also been observed. GBM tumours with low glutamine-synthesising capacity are found in the proximity of glutamine-synthesising astrocytes (Tardito et al, 2015).

High expression of transporters can facilitate the uptake of amino acids from the extracellular milieu and is associated with poor prognosis in some tumours (Kaira et al, 2012; Bhutia et al, 2015). Amino acids can also be derived from intact proteins taken up from the interstitial fluid. Cells transformed with oncogenic Ras have increased uptake of extracellular material via a process known as macropinocytosis (Commissio et al, 2013; Kamphorst et al, 2015). Curiously, although protein-derived carbons were found disseminated in various central metabolism pathways, the cyto-static effects of pharmacologically inhibited macropinocytosis could be overcome by glutamine metabolites. This finding may suggest that a primary function of macropinocytosis is to provide glutamine because, unlike its relative enrichment in the mammalian circulation, glutamine is not found at higher frequency compared with other amino acids in proteins (King and Jukes, 1969).

Whether and how biomolecules are mobilised from the surrounding tumour cells is relevant for further understanding and interfering with the metabolic interplay between the tumour stroma and cancer. Cancer cells are known to excrete microvesicles, such as exosomes, which contain various biomolecules, including RNA, DNA and proteins, and mediate intercellular
communication (D’Souza-Schorey and Clancy, 2012). Emerging evidence suggests that metabolites may also be part of the exosomal cargo (Zhao et al, 2016). An alternative mechanism could involve the internalisation of entire cells, a recently described phenomenon named enosis (Overholtzer et al, 2007). On detachment from extracellular matrix, some cells are engulfed by their neighbours, wherein they are degraded in lysosomes, a prime site for amino-acid storage. The fate of the cellular degradation products is not clear; however, they could provide a readily available source of metabolic fuel. It is possible that amino acids are indiscriminately used as nutrient sources and analysis of carbon sources for biomass production points to a significant contribution of amino acids as biosynthetic precursors for protein (Hosios et al, 2016). However, there is ample evidence for specific, non-redundant functions of some amino acids.

Serine is a non-essential amino acid that can be synthesised from glucose, although some cells import it, depending on their genetic background. Cells lacking functional p53 are more sensitive to serine deprivation both in culture and when grown as xenografts in mice (Maddocks et al, 2013). Serine is important for de novo synthesis of ATP, which may have a broad influence on cellular metabolism. Among others, serine-derived ATP provides the adenosine moiety of S-adenosyl-methionine, a key methyl-donor for methylation reactions that regulate epigenetic gene expression (Locasale, 2013; Figure 1). Serine catabolism through the same pathway also provides a significant source of NADPH for lipid synthesis (Fan et al, 2014). Branched-chain amino acids have long been linked to proliferative signaling, as activators of the mechanistic target of rapamycin pathway. Branched-chain amino acid catabolism through branched chain amino acid transferases may also provide an alternative source of metabolic precursors to sustain glioblastoma proliferation (Tonjes et al, 2013).

Together, the observations above highlight potential roles of the tumour niche, and in particular fibroblasts, as a complementary source for alternative nutrients to those provided by the circulation. However, cancer cells may engage in further metabolic interplay with other cell types in their vicinity in a way that influences tumour progression.

**INFLUENCE OF METABOLISM ON CELLULAR DYNAMICS IN THE TUMOUR MICROENVIRONMENT**

The role of the immune system to tumorigenesis is complex, and although in some settings inflammation has a tumour-promoting role, it is also clear that evading recognition by the immune system is a cardinal feature of cancer. The metabolic needs of immune cells implicated in tumorigenesis vary widely depending both on their subtype and activation status (Pearce et al, 2013; O’Neill et al, 2016).

Tryptophan is a precursor for de novo synthesis of NAD (Figure 3A). The first step of tryptophan metabolism is catalysed by indoleamine dioxygenase or tryptophan dioxygenase (IDO and TDO, respectively), which produce N-formyl-kyurenine, a precursor of kynurenine. Kynurenine is an endogenous ligand for aryl hydrocarbon receptor (AhR), a transcription factor also known to respond to environmental toxins. In gliomas, high TDO expression and associated kynurenine levels lead to increased AhR activity to promote tumorigenesis (Opitz et al, 2011). In contrast, mouse liver cancer is promoted by suppression of tryptophan catabolism (Tummalra et al, 2014). This was attributed to the decreased NAD production that results in suboptimal activity of the NAD-dependent DNA repair enzyme poly-ADP ribose polymerase.

The fact that both increased or decreased tryptophan catabolism are associated with tumorigenesis, albeit at different tissues, is seemingly contradictory. Intriguingly, in the same model of liver cancer, there is increased IL-17A due to infiltrating T_h17 cells, which contributes to an inflammatory environment that promotes steatosis, a predisposing factor to hepatocellular carcinoma (Gomes et al, 2016). Aryl hydrocarbon receptor is essential for T_h7 differentiation and tryptophan promotes T_h17 differentiation in culture (Veldhoen et al, 2008; Veldhoen et al, 2009). It is possible that a reciprocal relationship has been involved in kynurenine and NAD production, where diversion of tryptophan carbons to kynurenine depletes precursors for NAD synthesis and vice versa. Alternatively, suppressed tryptophan catabolism may be occurring early enough in the HCC model, leading to increased available tryptophan thereby providing a favourable niche for T_h17 differentiation (Figure 3A).

In activated T cells, PEP produced through glycolysis inhibits the sequestration of calcium in the endoplasmic reticulum (ER) by binding to and allosterically inhibiting sarkoplasmic/ER calcium ATPase (Figure 3B). This leads to a sustained increase in cytoplasmic calcium to activate NFAT, a transcription factor that mediates anti-tumour T-cell functions (Ho et al, 2015). In a mouse model of melanoma, glucose concentrations in the tumour interstitial fluid were 15 times lower than in the circulation due to high glycolysis by the tumour. Concomitantly, infiltrating tumour lymphocytes exhibited signs of glucose deprivation and decreased NFAT activity. Upregulation of PEP production in T cells by overexpression of PEP carboxykinase, preserved PEP levels under glucose-poor conditions and ameliorated tumour clearance. Intriguingly, signalling downstream of the PD-L1 receptor in cancer cells enhances tumour glycolysis (Chang et al, 2015), so immunotherapies targeting PD-L1 suppress tumour growth not only by enabling better tumour recognition by the immune system but also by interfering with tumour glycolysis.

The role of glucose metabolism in the stroma extends to endothelial cells, which are key components of new blood vessels that feed tumours. In diverse pathological settings, endothelial cell proliferation is accompanied by increased glycolysis that can be suppressed by inhibition of the glycolytic enzyme phosphofructokinase-2/fructose-2,6-biphosphatase 3 (De Bock et al, 2013; Schoors et al, 2014). Phosphofructokinase-2/fructose-2,6-biphosphatase 3-dependent glycolysis, and the ensuing production of ATP, is also required for essential cytoskeletal rearrangements of pioneer cells, known as tip cells, in newly forming vessels (De Bock et al, 2013; Cruys et al, 2016). In parallel, fatty acid oxidation, which could also potentially sustain ATP production, supports the synthesis of precursors in endothelial cells for nucleotide biosynthesis (Schoors et al, 2015).

These findings highlight the possibility that targeting metabolic pathways shared between cancer and stromal cells could provide a multi-pronged approach for cancer therapy. Nevertheless, they also illustrate that a deeper, systematic analysis of immune cell metabolism in various tumours would be required to evaluate the feasibility of this idea. For example, signals that are best produced by limiting glucose catabolism in tumours; however, limiting glucose uptake in tumours, instead, may be preferable, because it would be predicted to both undermine cancer metabolism, as well as restore the function of tumour-infiltrating T cells and endothelial cells. The latter could permit the maintenance of blood vessels necessary for the delivery of therapeutic agents to the tumours. Furthermore, although the above examples focus on T cells, given the importance of specific metabolic pathways on the function of almost every immune cell type studied to date, similar paradigms are likely applicable for other immune cell types. Ultimately, it is likely that the dynamics of nutrients in the tumour microenvironment, in addition to cell-intrinsic metabolic dependencies of immune cells may orchestrate the cellular profile of the stroma within each tumour.
Figure 3. Paradigms of cancer–immune cell interactions. (A) Tryptophan metabolism yields the intermediate kynurenine, which promotes glioblastoma development by activating the aryl hydrocarbon receptor, a transcription factor that controls the expression of pro-tumorigenic genes. A downstream product of further kynurenine catabolism is NAD, which, among others, is an essential co-factor for the DNA repair enzyme poly-ADP ribose polymerase (PARP). Suppression of NAD synthesis by oncogenic signalling in liver tumours leads to increased genomic instability, thereby promoting tumorigenesis. T\(_4\)17 cell differentiation can be influenced by tryptophan metabolites and T\(_4\)17-mediated inflammation has been implicated in liver cancer. Whether tryptophan metabolism in cancer cells influences tumour progression by modulating immune cells remains to be seen. (B) Metabolic competition for glucose between cancer cells and tumour-infiltrating T cells. In the proximity of highly glycolytic cancer cells, T cells fail to sustain cytoplasmic calcium levels necessary to activate the NFAT transcription factor, which mediates anti-tumour responses of T cells. The immunosuppressive molecule PD-L1 in cancer cells, may further promote glucose metabolism by signalling through the mechanistic target of rapamycin (mTOR) pathway, in addition to suppressing T cells via interaction with PD-1. ER, endoplasmic reticulum; NFAT, nuclear factor of activated T cells; PD-1, programmed cell death protein 1; PD-L1, PD ligand 1; PEP, phosphoenolpyruvate; SERCA, sarcoplasmic/endoplasmic reticulum calcium ATPase; TCR, T-cell receptor; TDO, tryptophan dioxygenase.
The microenvironments of various tumours are heterogeneous, partly because they integrate the varying metabolic behaviours of multiple cell types. Constant recruitment and turnover of these cells in conjunction with distinct cancer cell metabolic needs influence the dynamics of tumour metabolism through the various stages of cancer development. As a result, although, clearly, some of the metabolic characteristics of cancer cells are determined by the underlying genetic background, it is hard to conceive a single metabolic profile even for one type of cancer in the context of a constantly evolving metabolic landscape within the tumour microenvironment.

Studies of cancer metabolism in living higher organisms are uncovering the influence of metabolic interactions with the proximal environment. In addition, these experimental systems can reveal the influence of distal factors, such as nutrient metabolism via organs other than where the tumour is growing, or the resident microflora, the role of which in tumorigenesis is indicated by epidemiological evidence. At the same time, although yielding a physiological picture of tumour metabolism, these factors further convolute the process of pinpointing the source of specific metabolic phenotypes (Pichumani et al, 2016), and this may complicate the design of strategies for targeted therapeutics.

The development of imaging methods to study metabolism at the single-cell level in autochthonous settings will be invaluable in overcoming such limitations. In parallel, as we better understand the microenvironmental factors that influence the metabolic behaviours of cancer cells in physiological settings, there is a persistent incentive to successfully translate this knowledge into meaningful cell culture conditions. The advantages of using primary tumour cells isolated from mouse models or patients can be further broadened by mimicking tumour microenvironment factors, such as oxygen, nutrient and extracellular matrix conditions, which, in some settings, allow the recapitulation of in vivo metabolic behaviours also in vitro (Bensaad et al, 2014; Tardito et al, 2015). Furthermore, screening, testing and validation of new therapeutics can be tremendously expedited and scaled up in cultured cells.

Finally, appreciating the metabolic needs of both epithelial and stromal cells not only in fully-formed, proliferative tumours, but throughout tumour development may expand the scope of targeting metabolism for therapeutic purposes also for cancer prevention.

ACKNOWLEDGEMENTS

Work in the author’s lab related to the content of this review is supported by European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 642738; and by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001033), the UK Medical Research Council (FC001033) and the Wellcome Trust (FC001033).

CONFLICT OF INTEREST

The author declares no conflict of interest.

REFERENCES

Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, Thomas CJ, Vander Heiden MG, Cantley LC (2011) Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334: 1278–1283.

Balestra AP, Koster G, Guillermier C, Hirst EM, MacRae JL, Lechene CP, Postle AD, Gould AP (2015) Antioxidant role for lipid droplets in a stem cell niche of Drosophila. Cell 163: 340–353.

Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM, Pinnick KE, Wiigfield S, Buffa FM, Li JL, Zheng Q, Wakelam MJ, Karpe F, Schulze A, Harris AL (2014) Fatty acid uptake and lipid storage induced by HIF-1alpha contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep 9: 349–365.

Bhutia YD, Babu E, Ramachandran S, Ganapathy V (2015) Amino Acid transporters in cancer and their relevance to ‘glutamine addiction’: novel targets for the design of a new class of anticancer drugs. Cancer Res 75: 1782–1788.

Buescher JM, Antoniewicz MR, Boros LG, Burgess SC, Brunengraber H, Clish CB, DeBerardinis RJ, Feron O, Frezza C, Ghesquiere B, Gottlieb E, Hiller K, Jones RG, Kamphorst JJ, Kibbey RG, Kimmelman AC, Locasale JW, Lunt SY, Maddocks OD, Malloy C, Metzger K, Munger J, Noh K, Rabinowitz JD, Raiser M, Sauer U, Stephanopoulos G, St-Pierre J, Tennant DA, Wittmann C, Vander Heiden MG, Vazquez A, Vosudk S, Young JD, Zamboni N, Fendt SM (2015) A roadmap for interpreting (13)C metabolite labeling patterns from cells. Curr Opin Biotechnol 34: 189–201.

Cardaci S, Zheng L, MacKay G, van den Broek NJ, MacKenzie ED, Nixson C, Stevenson D, Tumanov S, Bulusu V, Kamphorst JJ, Vazquez A, Fleming S, Schiavi F, Kalna G, Blyth K, Strathdee D, Gottlieb E (2015) Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat Cell Biol 17: 1317–1326.

Chandel NS, Maltepe E, Goldwasser E, Mathieeu CE, Simon MG, Schumacker PT (1998) Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 95: 11175–11170.

Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Ginind M, Gubin MM, van der Windt GJ, Tocn E, Schreiber RD, Pearce RJ, Pearce EL (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162: 1229–1241.

Chaudhuri VK, Saltzer GG, Dick SA, Buckman MS, Sordella R, Karoly ED, Mohney R, Stiles BM, Elemento O, Altorki NK, McGrave TE (2013) Metabolic alterations in lung cancer-associated fibroblasts correlate with increased glycolytic metabolism of the tumor. Mol Cancer Res 11: 579–592.

Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Mates JM, DeBerardinis RJ (2011) Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci USA 108: 8674–8679.

Christen S, Loredente D, Schmieder R, Broekaert D, Metzger K, Voss E, Elia I, Buescher JM, Orth MF, Davidson SM, Grenouewld TD, De Bock K, Fendt SM (2016) Breast cancer-derived lung metastases show increased pyruvate carboxylase-dependent anaplerosis. Cell Rep 17: 837–848.

Comforder SA, Huang Z, Du X, Wang Y, Cai L, Wiktiewicz AK, Walters H, Tantawy MN, Fu A, Manning HC, Hortod J, Hammer RE, McNight SL, Tu BP (2014) Acetate dependence of tumors. Cell 159: 1591–1602.

Commissio C, Davidson SM, Soydaner-Axelozoglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Noafal M, Drebijn IA, Thompson CB, Rabinowitz JD, Metallo CM, Vander Heiden MG, Bar-Sagi D (2013) Macropinocytosis of pyruvate is an amino acid supply route in Ras-transformed cells. Nature 497: 633–637.

Cruys B, Wong BW, Kuchnio A, Verdege D, Cantelmo AR, Conradi LC, Vandekeere S, Bouche A, Cornelissen I, Vincikier S, Merks RM, Dejana E, Gerhardt H, Dewerchin M, Bentley K, Carmeliet P (2016) Glycolytic regulation of cell rearrangement in angiogenesis. Nat Commun 7: 12240.

De Souza-Sorey C, Clancy JW (2012) Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev 26: 1287–1299.

Davidson SM, Papagiannakopoulos T, Olenchock BA, Heyman JE, Keibler MA, Luengo A, Bauer MR, Jha AK, O’Brien JP, Pierce KA, Gui DY, Sullivan LB, Wasylwenko TM, Subbaraj L, Chin CR, Stephanopoulos G, Mott BT, Jacks T, Clish CB, Vander Heiden MG (2016) Environment impacts the metabolic dependencies of ras-driven non-small cell lung cancer. Cell Metab 23: 517–528.

De Bock K, Georgiadou M, Schoors S, Geusens R, Olenchock BA, Keibler MA, Luengo A, Bauer MR, Peck B, Lord S, Collins JM, Pinnick KE, Wiigfield S, Buffa FM, Li JL, Zheng Q, Wakelam MJ, Karpe F, Schulze A, Harris AL (2014) Fatty acid uptake and lipid storage induced by HIF-1alpha contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep 9: 349–365.
Tumour microenvironment and cancer metabolism

Tumor microenvironment and cancer metabolism

BRITISH JOURNAL OF CANCER

DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, DeBerardinis RJ, Chandel NS (2016) Fundamentals of cancer metabolism. Sci Adv 2: e1600200.

Fan J, Ye J, Kamphorst JJ, Chung MK, Fan J, Rabinowitz JD (2014) Quantitative flux analysis reveals folate-dependent NDPH production. Nature 510: 298–302.

Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJ, Snell C, Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, Jiang L, Ko B, Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, Tsui YC, Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Israelsen WJ, Vander Heiden MG (2010) ATP consumption promotes cancer proliferation and prevents premature senescence in cancer cells. Cell Metab 17: 751–764.

Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G (2013) Metabolic targets for cancer therapy. Nat Rev Drug Discov 12: 829–846.

Gesques B, Wong BW, Kuchnio A, Carmeliet P (2014) Metabolism of stromal and immune cells in health and disease. Nature 511: 167–176.

Gomes AL, Teijeiro A, Buren S, Tummala KS, Yilmaz M, Waisman A, Theurillat JP, Pernaa C, Djouder N (2016) Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell 30: 161–175.

Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, Jiang L, Ko B, Skelton R, Loutad L, Wodzak M, Klimko C, McMillan E, Butt Y, Ni M, Oliver D, Torrealba J, Malloy CR, Kernstine K, Lennkini RE, DeBerardinis RJ (2016) Metabolic heterogeneity in human lung tumors. Cell 164: 681–694.

Ho PC, Bhuinjak JD, Macintyre AN, Staron M, Liu X, Amezquita R, Tsu YC, Cui G, Micevic G, Perales JC, Kleinsh M, Abel ED, Insogna KL, Feske S, Locasale JW, Benson MG, Rathmell JC, Kaech SM (2015) Mitochondrial membrane potential are necessary for diverse biological responses. Cancer Res 75: 788–798.
Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. *Cell Metab* 3: 187–197.

Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. *Cell Metab* 23: 27–47.

Pearce EL, Poffenberger MC, Chang CH, Jones RG (2013) Fueling immunity: insights into metabolism and lymphocyte function. *Science* 342: 1242454.

Peck B, Schug ZT, Zhang Q, Dankworth B, Jones DT, Smethurst E, Patil R, Mason S, Jiang M, Saunders R, Howell M, Mitter R, Spencer-Dene B, Stamp G, McGarry L, James D, Shanko E, Aboagye EO, Critchlow SE, Leung HY, Harris AL, Wakelam MJ, Gottlieb E, Schulze A (2016) Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. *Cancer Metab* 4: 6.

Pichumani K, Mashimo T, Vemireddy V, Kovacs Z, Ratnakar J, Mickey B, Malloy CR, DeBerardinis RJ, Bachoo RM, Maher EA (2016) Hepatic gluconeogenesis influences (13)C enrichment in lactate in human brain tumors during metabolism of [1,2-(13)C]acetate. *Neurochem Int* 97: 133–136.

Schäfer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, Brugge JS (2009) Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. *Nature* 461: 109–113.

Schoors S, Broning U, Missiaen R, Queiroz KC, Borgers G, Elia I, Zechin A, Cantelmo AR, Christen S, Goveia J, Heggermont W, Godde L, Vinckier S, Van Veldhoven PP, Eelen G, Schoonjans L, Gerhardt H, Dewerchin M, Baes M, De Bock K, Ghesquière Z, Lunt SY, Fendt SM, Carmeliet P (2015) Fatty acid carbon is essential for dNTP synthesis in endothelial cells. *Nature* 520: 192–197.

Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquière B, Cauwenberghs S, Kuchnio A, Wong BW, Quaegebeur A, Goveia J, Bifari F, Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. *Cell Metab* 23: 57–71.

Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, Goodwin LM, Smethurst E, Mason S, Blyth K, McGarry L, James D, Shanks E, Kalna G, Saunders RE, Jiang M, Howell M, Lassailly F, Thin AZ, Spencer-Dene B, Stamp G, van den Broek NJ, Mackay G, Bulusu V, Kamphorst JJ, Tardito S, Strachan D, Harris AL, Aboagye EO, Critchlow SE, Wakelam MJ, Schulze A, Gottlieb E (2015) Acetyl-CoA synthetase 2 mediates adaptation to environmental toxins. *Nature* 453: 108–109.

Sellers K, Fox MP, Bouamra 2nd M, Stone SP, Higashi RM, Miller DM, Wang Y, Yan J, Yuneva MO, D’Ambrosio MR, Lane AN, Fan TW (2015) Fatty acids are the preferred source of membrane lipids in proliferating fibroblasts. *Cancer Metab* 3: 667–676.

Shimizu T, Benyamini T, Gottlieb E, Sharan R, Ruppin E (2011) Genotype-phenotype metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect. *PloS Comput Biol* 7: e1002018.

Souza CM, Bancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, Kremer D, Hwang RF, Witkiewicz AK, Ying H, Asara JM, Evans RM, Cantley LC, Lyssiotis CA, Kimmelman AC (2016) Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. *Nature* 536: 479–483.